RESUMEN

BACKGROUND: Deposition of C4d in peritubular capillaries of renal graft is normally associated with the presence of antibody-mediated rejection. The clinical impact of its presence in patients with renal transplant in Colombia is uncertain, as well as the association in acute rejection and the response to the management and survival of the graft. The aim of this study was to determine the risk of having positive C4d in biopsies of patients with episodes of acute cellular rejection. METHODS: We retrospectively reviewed 226 biopsies of kidney transplantation, all of them with acute rejection and histopathological findings classified according to Banff criteria 2009 and performed between January 2005 and December 2012 for graft dysfunction. C4d staining was performed by immunohistochemistry. RESULTS: C4d staining was positive in 25 of 226 biopsies. Rejection time in patients with positive C4d was 15 months in average vs 8 months with negative C4d. CONCLUSIONS: With the use of a multivariate analysis, we found that the unique risk for C4d in our population was the positive panel reactive antibodies and elapsed time between transplant and the rejection (odds ratio: 2.12, P = .034) and that the other variables analyzed are not related to the expression of C4d.

Asunto(s)

RESUMEN

The objectives of this study were (1) to determine the effect of rabbit seminal plasma on LH secretion and ovulation using the llama animal model as an in vivo ovulation bioassay and (2) to determine the effect of llama or rabbit seminal plasma on ovulation induction in the rabbit model. In Experiment 1, llamas with a growing follicle ≥8mm in diameter were assigned randomly to one of three groups (n=5 per group) and given an intramuscular dose of 1mL of: (a) llama seminal plasma, (b) rabbit seminal plasma, or (c) phosphate buffered saline (PBS; negative control). Blood samples for LH measurement were taken every 15 min from 1.5 h before to 8 h after treatment (Day 0: starting of treatment). Llamas were examined by ultrasonography every 12h from treatment to ovulation, and then every other day until Day 16 after treatment to evaluate corpus luteum (CL) development. Blood samples for progesterone measurement were taken every other day from Day 0 to Day 16. Ovulation was detected in 4 of 5, 5 of 5, and 0 of 0 llamas treated with llama or rabbit seminal plasma and PBS, respectively (P<0.001). After treatment, plasma LH concentration increased and decreased (P<0.01) in the llama and rabbit seminal plasma group but not in the PBS-treated group. No differences were observed on CL development (P≥0.3) and progesterone secretion (P>0.05) between both seminal plasma treated groups. In Experiment 2, receptive female rabbits (n=5-7 per group) were given an intramuscular dose of: (a) 0.5, (b) 1.0 and (c) 2.0mL of either rabbit or llama seminal plasma, (d) 0.5mL PBS (negative control), or (e) 25µg of gonadoreline acetate (GnRH; positive control). Does were submitted to laparotomy 24-36 h after treatment to determine the ovulatory response and the presence of antral and hemorrhagic anovulatory follicles. Ovulation sites (7.0±0.6) were only detected in GnRH-treated does (P<0.01). There was an increase (P<0.01), in the total number of follicles (antral plus hemorraghic follicles) in those females treated with 1mL of rabbit seminal plasma and there was a tendency (P=0.08) for more hemorrhagic anovulatory follicles in does treated with 1.0 and 2.0mL of either rabbit or llama seminal plasma. Results document the presence of OIF in the seminal plasma of rabbits. The differential ovulatory response between species, however, requires further investigation.

Asunto(s)

RESUMEN

AIM: The purpose of this study was to evaluate if superior glycaemic control could be achieved with Avandamet® (rosiglitazone/metformin/AVM) compared with metformin (MET) monotherapy, and if glycaemic effects attained with AVM are durable over 18 months of treatment. Bone mineral density (BMD) and bone biomarkers were evaluated in a subgroup of patients. METHODS: This was a phase IV, randomized, double-blind, multi-centre study in 688, drug naÏve, male and female patients who had an established clinical diagnosis of type 2 diabetes mellitus (T2DM). Patients were randomized in a 1 : 1 ratio either to AVM or MET. RESULTS: As initial therapy in patients with T2DM, AVM was superior to MET in achieving statistically significant reductions in glycated haemoglobin (HbA1c) (p < 0.0001) and fasting plasma glucose (FPG) (p < 0.001), with more patients reaching recommended HbA1c and FPG targets for intensive glycaemic control. The glycaemic effects attained with AVM compared to MET monotherapy were durable over 18 months of treatment. In the bone substudy, AVM was associated with a significantly lower BMD in comparison with MET at week 80 in the lumbar spine and total hip (p < 0.0012 and p = 0.0005, respectively). Between-treatment differences were not statistically significant for distal one-third of radius BMD, femoral neck BMD or total BMD. CONCLUSION: Superior glycaemic control was achieved with AVM compared with MET monotherapy. The superior glycaemic effects were shown to be durable over 18 months of treatment. AVM was associated with a significantly reduced BMD in comparison with MET at week 80 in the lumbar spine and total hip.

Asunto(s)

RESUMEN

Validation studies were carried out on a multi-residue screening method for anilinic type beta-agonists (clenbuterol, mabuterol, brombuterol, cimaterol, cimbuterol, mapenterol, clenpenterol) and a method for the phenolic type beta-agonist, salbutamol, in bovine liver. The validation was performed according to the European Union Commission Decision 2002/657/EC (European Commission 2002), which establishes criteria and procedures for the determination of parameters such as the detection capability (CCbeta), specificity, stability of standard solutions and stability of the analyte in matrix. CCbeta values for the eight target compounds were between 0.25 and 0.5 microg kg(-1). The stability of standard solutions and analytes in matrix and the specificity of the antibody were characterized. The methods are applicable for qualitative screening of beta-agonists for regulatory programmes according to European Union performance requirements, or as a semi-quantitative research tool for known target compounds.

Asunto(s)

RESUMEN

The obesity epidemic is prevalent in Latin America. Our surgical team has had a significant number of consultations from parents and doctors of the obese child population. A case in a morbidly obese 12-year-old is hereby reported.

Asunto(s)

RESUMEN

Se presenta el caso de una paciente de 20 años con diagnostico de insuficiencia renal cronica terminal y cardiopatia dilatada a quien se le practicó trasplante simultáneo de corazón - rinon de un mismo donante, en el Hospital Clinica San Rafael de Santafe de Bogota, D. C., en octubre de 1996. Recibio terapia secuencial de inmunosupresion. Los dos injertos funcionan adecuadamente y no ha presentado episodios de rechazo agudo.

Asunto(s)

RESUMEN

Se presenta el caso de un paciente de 50 años de edad con antecedente de trasplante renal de donante vivo relacionado quien despues del segundo ciclo de tratamiento para rechazo agudo del trasplante presenta perforacion espontánea del colon, haciendose evidente la dificultad para el diagnostico temprano de esta patologia en pacientes que reciben algun tipo de inmunosupresion. Al rededor del caso se discute y revisa el tema de la incidencia de los inmunosupresores sobre la integridad del colon.

Asunto(s)

Asunto(s)

RESUMEN

Presenta folleto elaborado por el Centro de Información y Servicios de Asesoría en Salud (CISAS), con el objetivo de promover la salud en la comunidad con el uso de títeres como una manera divertida de ayudar a niños y niñas a aprender a cerca de la salud. Este folleto contiene guiones cortos, alegres, dinámicos y de fácil montaje. Sus contenidos son sencillos y comprensibles lo que da paso al diálogo fluido y espontáneo a los niños y niñas

Asunto(s)

Asunto(s)